IN8BIO INC. - COMMON

0.2265

08-October-24 12:30:18

15 minutes delayed

Stocks

-0.0285

-11.18%

Today's range

0.2170 - 0.2599

ISIN

N/A

Source

NASDAQ

IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

11 Aug 2021 08:00:01 By Nasdaq GlobeNewswire
IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors

04 Aug 2021 08:00:01 By Nasdaq GlobeNewswire
IN8bio Announces Pricing of Initial Public Offering

30 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

<<
<
2
3
4
5
6
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.